LUDWIG ENTERPRISES, INC.

S-1/A amended

Price $8.98 · 1,670,379 shares

Ludwig Enterprises, Inc. is conducting a firm commitment public offering of 1,670,379 common units, each consisting of one share of common stock and one warrant, at an assumed offering price of $8.98 per unit. The offering includes a 1-for-200 reverse stock split, pending FINRA approval, to qualify for stock exchange listing. The company aims to list its common stock on an exchange under the symbol 'RVLA' and warrants under 'RVLAW'. The offering is contingent on successful listing and reverse stock split. The company remains an emerging growth company with no revenue to date, focusing on genomics-based inflammation-related disease testing.

S-1/A amended

Price $4.00 · 3,750,002 shares

Ludwig Enterprises, Inc. is conducting a firm commitment public offering of 3,750,002 common units, each consisting of one share of common stock and one warrant. The offering includes a proposed 100:1 reverse stock split, intended to qualify for a stock exchange listing. The company aims to list its common stock on an unspecified exchange under the symbol 'RVLA' and warrants under 'RVLAW', contingent on approval. The offering price is $4.00 per unit, with underwriters granted a 45-day option to purchase additional units. The company has not yet sold products and relies on a single proprietary test for inflammation-related chronic diseases.

S-1/A amended

Ludwig Enterprises, Inc. is conducting an IPO to raise capital through the public offering of its common stock. The company, a genomics-based diagnostic firm, aims to launch its proprietary mRNA testing kits for chronic disease detection. The offering includes a reverse stock split to meet listing requirements and conversion of convertible preferred stock and notes into common shares. The company faces risks related to its early-stage operations, reliance on regulatory approvals, and market acceptance.

S-1 filed

Ludwig Enterprises, Inc. is conducting an S-1 registration for a public offering of common stock, aiming to uplist to a stock exchange. The company plans a reverse stock split, conversion of convertible preferred stock and notes into common shares, and a name change to Revealia, Inc. The offering includes a firm commitment underwriting by ThinkEquity, with proceeds intended for debt repayment and operational growth. The company develops mRNA genetic testing kits for inflammatory disease detection but has not yet generated revenue.

424B1 priced

Price $0.40 · 47,000,000 shares

Ludwig Enterprises, Inc. filed a 424B1 prospectus supplement updating the offering price of its 47,000,000 common shares from $0.50 to $0.40 per share. This adjustment impacts dilution and gross proceeds but does not alter the underlying registration statement. The filing incorporates by reference recent financial reports and emphasizes forward-looking statements subject to risks.

8-A12B effective

Ludwig Enterprises, Inc. filed Form 8-A to register its common stock under Section 12(g) of the Securities Exchange Act. The filing incorporates by reference the description of securities from its S-1 registration statement (File No. 333-271439), which was initially filed in April 2023. The company focuses on developing mRNA genetic testing kits and anti-inflammatory nutritional supplements, with the 8-A emphasizing securities registration rather than offering details.

424B2 filed

Price $0.50 · 47,000,000 shares · Gross proceeds $23,500,000

Ludwig Enterprises, Inc. is offering 47,000,000 shares of common stock at $0.50 per share, self-underwritten by President Anne B. Blackstone. The offering includes convertible notes convertible into shares at 80% of the offering price. The company, an emerging growth company, focuses on mRNA genomics technology for disease detection and anti-inflammatory supplements. Risks include limited market liquidity, control by convertible preferred stock, regulatory uncertainties, and dependence on key personnel.

EFFECT effective

Ludwig Enterprises, Inc. has received effectiveness for its S-1 registration statement, enabling the offering of 47,000,000 shares of common stock at $0.30-0.60 per share. The company will self-underwrite the offering through its President, Anne B. Blackstone. Convertible notes totaling $1,040,000 may convert into shares at 80% of the offering price. The company is an emerging growth entity with limited trading volume and significant risks, including speculative nature, voting control by preferred stockholders, and no guaranteed market for its securities.

S-1/A amended

Price $0.45 · Range $0.30 to $0.60 · 47,000,000 shares

Ludwig Enterprises, Inc. is a genomics technology company developing mRNA genetic testing kits and natural anti-inflammatory supplements. The company is offering 47,000,000 shares of common stock at an estimated price range of $0.30-0.60 per share, with proceeds intended for business operations and product development. The offering includes convertible notes convertible into common stock at 80% of the offering price. The company faces risks related to its speculative nature, limited market history, and control by convertible preferred stockholders.

S-1/A amended

Range $0.75 to $1.25 · 47,000,000 shares

Ludwig Enterprises, Inc. is conducting an IPO to raise capital through the sale of 47,000,000 shares of common stock at an estimated price range of $0.75-$1.25 per share. The company develops mRNA genetic testing kits and anti-inflammatory nutritional supplements, targeting the health and wellness market. Proceeds will fund operations, product development, and marketing. The offering includes convertible notes that may convert into common stock, and the company has a history of net losses. Its common stock is quoted on the OTC PINK market, but trading volume is limited.

S-1/A amended

Price $1.00 · Range $0.75 to $1.25 · 47,000,000 shares

Ludwig Enterprises, Inc. is offering 47,000,000 shares of common stock at an estimated price of $0.75-$1.25 per share. The company develops mRNA genetic testing kits and anti-inflammatory nutritional supplements targeting inflammatory disease monitoring and management. The offering is self-underwritten by its President, Anne B. Blackstone, with proceeds intended for operations and product development. The company faces risks including limited market liquidity, lack of operating history, and control by convertible preferred stockholders.

S-1/A amended

Range $0.75 to $1.25 · 47,000,000 shares

Ludwig Enterprises, Inc. is a genomics technology company developing mRNA genetic testing kits and anti-inflammatory nutritional supplements. The company is offering 47,000,000 shares of common stock at an estimated price of $0.75-$1.25 per share, with proceeds intended for product development, marketing, and operational costs. The offering includes convertible notes that may convert into common stock at 80% of the offering price. The company faces risks related to its history of losses, limited market liquidity, and control by convertible preferred stockholders.

S-1/A amended

Price $1.00 · Range $0.75 to $1.25 · 47,000,000 shares

Ludwig Enterprises, Inc. is conducting an IPO to raise capital through the sale of 47,000,000 shares of common stock at an anticipated price range of $0.75-1.25 per share. The company develops mRNA genetic testing kits and anti-inflammatory nutritional supplements targeting inflammatory disease detection and management. The offering includes convertible notes eligible for conversion into common stock at 80% of the offering price. The company operates in a competitive market with significant risks related to commercialization, capital requirements, and regulatory uncertainties.

S-1/A amended

Range $0.75 to $1.25 · 47,000,000 shares

Ludwig Enterprises, Inc. is a genomics technology company developing mRNA genetic testing kits and anti-inflammatory nutritional supplements. The company is offering 47,000,000 shares of common stock at an anticipated price range of $0.75-$1.25 per share. The offering includes convertible notes eligible for conversion into common stock at 80% of the offering price. The company aims to commercialize its testing kits and supplements in the U.S. market, focusing on wellness clinics and direct-to-consumer channels. However, the offering carries significant risks, including limited market demand, competition, and reliance on management's ability to execute its business plan.

S-1/A amended

Range $0.75 to $1.25 · 47,000,000 shares

Ludwig Enterprises, Inc. is offering 47,000,000 shares of common stock in a self-underwritten, best-efforts offering. The company develops mRNA genetic testing kits and anti-inflammatory nutritional supplements. The offering includes convertible notes convertible into shares at 80% of the offering price. The company faces risks related to its history of losses, unproven products, and intense competition. The filing highlights plans to launch products in 2023 but notes uncertainties in market adoption and capital availability.

S-1 filed

Range $0.75 to $1.25 · 47,000,000 shares

Ludwig Enterprises, Inc. is offering 47,000,000 shares of common stock in an S-1 filing, aiming to raise capital through a self-underwritten, best-efforts offering led by CEO Anne B. Blackstone. The company develops mRNA genetic testing kits and anti-inflammatory supplements targeting inflammatory disease markers. The offering includes convertible notes convertible into shares at 80% of the offering price. The company faces risks related to market adoption, competition, and limited operational history.

DRS filed

Ludwig Enterprises, Inc. is registering 47,000,000 shares of common stock under Form S-1, aiming to raise capital through a self-underwritten, best-efforts offering. The company, focused on genomics technology and health-related products, faces significant risks including early-stage development, lack of revenue, audit concerns, and regulatory uncertainties. The offering price is set between $0.75 and $1.25 per share, with proceeds intended for business operations. The company's common stock is quoted on the OTC Pink market, but trading volume remains limited.